Lack of support for association between the KIF1B rs10492972[c] variant and multiple sclerosis
To the Editor:
In their recent communication, Aulchenko et al. 1 suggested that the rs10492972[C] variant of KIF1B increases susceptibility to multiple sclerosis. In an attempt to replicate this observation, we genotyped this variant in eight case-control and three trio-family collections (in total 22,854 individuals were considered, comprising 8,391 cases, 8,052 unrelated controls and 2,137 trio families). None of these studies showed evidence for a statistically significant association; more than half of the studies showed a trend in the opposite direction (Fig. 1) . Based on the odds ratio (OR) reported by Aulchenko et al. 1 (OR = 1.35), each of the collections we studied had >80% power to demonstrate association at the 5% significance level, except for the two smaller Australian studies; a population where association with this KIF1B variant has already essentially been excluded 2 . We also found no evidence for association with rs10492972 [C] in analyses that considered all of our data together or those that pooled our new data with the allele counts reported by Aulchenko et al. 1 (final P = 0.1). Given the P value originally reported by Aulchenko et al. 1 (P = 2.5 × 10 -10 ), it is important to consider why this association has not been replicated.
The genesis of the original claim for association is important. The genome-wide association study performed by Aulchenko et al. 1 was predicated on the notion that in a small genetically isolated population, risk alleles that are rare in the general population may have become concentrated and thereby can be more readily detected. However, there was limited power in using this approach due to the small sample size (45 cases and 195 controls), and no significant associations were identified in the initial genome-wide association study 1 . In this setting, the odds that a modestly associated variant (P = 0.0004) from a candidate gene is genuinely associated with the disease are unfavorable 3 . The possibility that perhaps this variant is relevant in The Netherlands, Sweden and Canada (the populations studied by Aulchenko et al. 1 ) but not elsewhere in the world seems unlikely considering the allele frequencies we have observed. In all of the collections we tested, the observed allele frequency was comparable with that seen in the European CEU HapMap samples (frequency = 0.34). However, in the study from Aulchenko et al. 1 , although all of the case groups showed a HapMap-consistent frequency for rs10492972 [C] , the frequency of this allele was reduced in the control groups (allele frequency in Dutch isolate controls was 0.21 and the allele frequency in pooled controls was 0.27). This is the reverse of what would be expected if the risk allele had been concentrated in the Dutch population. After testing, there is no meaningful allele frequency difference between the cases in our new data and those originally reported; however, a significant difference in the allele frequency between the two control groups was observed (P = 3.5 × 10 -16 ).
The Swedish population is the only one considered in the original report 1 that has been directly studied here. In the Swedish samples considered by Aulchenko et al. 1 (826 subjects and 997 controls), modest apparent association was reported, whereas in the nonoverlapping Swedish samples we typed (1,239 subjects and 736 controls), no association was found. Comparing these two Swedish data sets indicates that this divergence of results stems almost exclusively from a difference in allele frequency between the control groups. 
Hintzen et al. reply:
We share the authors' surprise that in a large dataset from several countries, they failed to reproduce the association between variation at the KIF1B locus and multiple sclerosis (MS) that we observed 1 . A role for KIF1B (kinesin family member 1B) in MS is biologically plausible given both the increasingly recognized role of kinesins in neurological disease and the recent report on Kif1b and myelination 2 . Our original observation has been replicated in a study of Canadian multiplex MS families 3 , which showed an odds ratio ( There is a striking difference between the allele frequency of rs10492972[C] in the controls in our study (pooled frequency = 0.27) and those in the IMSGC study (pooled frequency = 0.33). In our study, the controls from the Dutch genetic isolate appear to have a low allele frequency; this may suggest that our control group was biased in some way. We verified the frequency of the C allele in the Dutch isolate using an extended cohort 6 from the same genetically isolated population. This SNP was imputed with r 2 > 0.99 in a total of 2,385 people; the frequency of rs10492972[C] was 0.24, consistent with our previous results in this population (0.21), and was indeed substantially lower than that in the Dutch outbred population (the frequency in our MS study 1 was 0.34; the frequency in over 5,000 Dutch persons age 55 years and older from the population-based Rotterdam study cohort 7 was 0.31). This may be attributed to founder effects that could occur in some isolates. Differences in C-allele frequencies in the controls were also seen between our Swedish cohort (0.29) and the IMSGC Swedish cohort (0.31). It will be of interest to determine whether a joint analysis of the Swedish data from both studies shows an association between rs10492972[C] and MS.
One of the implications of the differences in allele frequency between our cohorts and those from The Netherlands and Sweden is that confounding due to population stratification may have led us to a false positive finding. A priori, a stratification error is not very likely, as it would have had to have occurred in each of the four different populations that we analyzed. Further, in our paper, we used EIGENSTRAT analysis to adjust for this type of confounding, and the pedigree disequilibrium test used for the multiplex families from Canada and the UK is not subject to confounding by population stratification.
The difference in ORs betwen our analysis and that of the IMSGC needs an explanation. One possibility for this difference is genotyping errors, which are often revealed as deviations from Hardy-Weinberg equilibrium (HWE). It is of note that both the genotype and allele frequencies were not in HWE in the IMSGC UK cohort (P = 0.04) and were borderline for the IMSGC Italian cohort (P = 0.08). When testing a single SNP, the inclusion of cohorts in which the controls are not in HWE violates standard practice in genetic epidemiology as well as the more recent Venice criteria for candidate gene studies 8 .
Another possibility for the difference in ORs is that of prevalence-incidence bias. If a gene is related to survival after the onset of disease, this may result in the observation of a wide range of ORs along various studies because of subtle differences in inclusion procedures. As our Dutch population cohort was ascertained relatively early in the disease phase, we investigated whether KIF1B allele frequencies showed a relation to age at diagnosis and to the time between age at diagnosis and age at study inclusion. Indeed, in our Dutch outbred cohort, we saw a borderline significant association between KIF1B genotype and age at diagnosis, with the age at diagnosis being an average of 2.8 years later in individuals with the KIF1B CC genotype (P = 0.09, 95% CI -0.4 to 6.0; see Supplementary Note for details). After we adjusted for these age differences, a nominally significant association remained between KIF1B genotype and time between the age at diagnosis and age at inclusion in the study, with the KIF1B CC genotype being associated with a shorter period between diagnosis and study inclusion; individuals with the CC genotype were included in the study an average of 2.4 years earlier than those without it (P = 0.02, 95% CI 0.3-4.5 year).
In conclusion, we are puzzled by the differences in allele frequencies between the controls in our study and those in the IMSGC. This issue, together with the deviations from HWE seen in the controls of the IMSGC and a possibility of incidence-prevalence bias, calls for further studies. Deep sequencing of KIF1B may also shed light on these questions.
